Propanc Biopharma, Inc. Common Stock

Propanc Biopharma, Inc. is a development-stage biopharmaceutical healthcare company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous proenzyme treatment intended as a therapeutic option for cancer treatment and prevention, which has completed pre-clinical studies. The company has research and collaboration agreements with the University of Jaén for the POP1 Program and with the University of Granada to develop a synthetic recombinant version of PRP. Formerly known as Propanc Health Group Corporation, it changed its name to Propanc Biopharma, Inc. in April 2017, was incorporated in 2007, and is based in Camberwell, Australia.

Biotech & Genomic Medicine▲2

Propanc Biopharma Signs MOU With Avance Clinical for First-in-Human Trial of PRP

Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical to collaborate on the clinical delivery of a planned Phase 1b First-in-Human trial for PRP, its lead investigational candidate for advanced solid tumors. The study will evaluate safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity in patients with advanced cancer. Avance Clinical brings more than 30 years of experience in early-phase oncology trials and offers advantages such as rapid ethics approval and significant R&D tax rebates in Australia. Propanc, headquartered in Melbourne since 2007, aims to capitalize on these benefits. CEO James Nathanielsz called the MOU an important milestone toward clinical evaluation, citing PRP's unique mechanism of action, low toxicity, and good tolerability for patients with limited treatment options.

PPCB ▲

Biotech & Genomic Medicine

RTTNews·73dRead more →